Screener / SEC EDGAR /CIK 0002014596 /10-K filed Feb 26, 2026, compared with Mar 3, 2025 /Numbers from the XBRL of the 10-Ks
NYSE Health care · Specialty Outpatient Facilities

Concentra Group Holdings Parent, Inc. CON

Compare with peers Embed
What it said it expected, against what it reported

3 targets with a reported result

Releases of the last 3 years
Above the range 1 above the last range given
Within the range 1 of 3 range targets
Below the range 1 below the last range given

The numbers CON said it expected, in its earnings releases, next to what it then reported for the same period.

Target by target

Each target, with the sentence it came from · release and 10-Q or 10-K

The last range givenReported, abovewithin or keptbelow or missed
TargetWhat the company saidReportedResult
EBITDA (company-defined)
Fiscal 2026
Given $450.00M to $470.00M release Jan 28, 2026
Kept $450.00M to $470.00M release Feb 26, 2026
– No standard number
The company's words
For full year 2026, Concentra expects to deliver the following results: … Adjusted EBITDA in the range of $450 million to $470 million release Jan 28, 2026
For full year 2026, Concentra expects to deliver the following results: … Adjusted EBITDA in the range of $450 million to $470 million release Feb 26, 2026
Free cash flow (company-defined)
Fiscal 2026
Given $200.00M to $225.00M release Jan 28, 2026
Kept $200.00M to $225.00M release Feb 26, 2026
– No standard number
The company's words
For full year 2026, Concentra expects to deliver the following results: … Free cash flow of $200 million to $225 million release Jan 28, 2026
For full year 2026, Concentra expects to deliver the following results: … Free Cash Flow of $200 million to $225 million release Feb 26, 2026
Capital expenditures
Fiscal 2026
Given $70.00M to $80.00M release Jan 28, 2026
Kept $70.00M to $80.00M release Feb 26, 2026
– Not reported yet
The company's words
Capital expenditures in the range of $70 million to $80 million A reconciliation of full year 2026 Adjusted EBITDA expectations to net income is presented in table VI of this release and a reconciliation of full year 2026 net cash provided by operating activities to Free Cash Flow, alongside a definition of Free Cash Flow, is presented in table VII of this release. release Jan 28, 2026
Capital expenditures in the range of $70 million to $80 million A reconciliation of full year 2026 Adjusted EBITDA expectations to net income is presented in table XIII of this release and a reconciliation of full year 2026 net cash provided by operating activities to Free Cash Flow, alongside a definition of Free Cash Flow, is presented in table XIV of this release. release Feb 26, 2026
Revenue
Fiscal 2026
Given $2.15B to $2.16B release Nov 6, 2025
Raised $2.25B to $2.35B release Jan 28, 2026
Kept $2.25B to $2.35B release Feb 26, 2026
Raised $2.36B to $2.38B release Nov 5, 2026
– Not reported yet
The company's words
In late stages of finalizing de novo pipeline for 2026 and beyond Development Nova and Pivot Onsite integrations progressing smoothly and largely complete Growing pipeline of bolt-on M&A opportunities of small occupational health center practices (1-5 locations) Raising FY 2025 guidance for Revenue ($2.145bn-$2.160bn) and Adjusted EBITDA1 ($425mm-$430mm). release Nov 6, 2025
For full year 2026, Concentra expects to deliver the following results: … Revenue in the range of $2.25 billion to $2.35 billion release Jan 28, 2026
For full year 2026, Concentra expects to deliver the following results: … Revenue in the range of $2.25 billion to $2.35 billion release Feb 26, 2026
Transition Services Agreement scheduled to formally expire in NovemberSEPARATION Completed leadership transition effective November 1, with Matt DiCanio as President & CEO, Tanner Newton as EVP & CFO, and Keith Newton as executive chairman of the Board LEADERSHIP Raising FY 2026 guidance for Revenue ($2.36bn-$2.38bn) and Adjusted EBITDA1 ($505mm-$510mm)GUIDANCE release Nov 5, 2026
EBITDA (company-defined)
Fiscal 2025 (ended Dec 31, 2025)
Given $410.00M to $425.00M release Jan 23, 2025
Kept $410.00M to $425.00M release Mar 3, 2025
Raised $415.00M to $430.00M release May 7, 2025
– No standard number
The company's words
For 2025, giving effect to the acquisition of Nova Medical Centers, Concentra expects to deliver the following results: … · Adjusted EBITDA in the range of $410 million to $425 million release Jan 23, 2025
For 2025, giving effect to the acquisition of Nova Medical Centers, Concentra expects to deliver the following results: … Adjusted EBITDA in the range of $410 million to $425 million release Mar 3, 2025
For 2025, Concentra now expects to deliver the following results: … Adjusted EBITDA in the range of $415 million to $430 million release May 7, 2025
Capital expenditures
Fiscal 2025 (ended Dec 31, 2025)
Given $80.00M to $90.00M release Jan 23, 2025
Kept $80.00M to $90.00M release Mar 3, 2025
Kept $80.00M to $90.00M release May 7, 2025
$82.33M
10-K filed 2026-02-26
Within the range
The company's words
For 2025, giving effect to the acquisition of Nova Medical Centers, Concentra expects to deliver the following results: … · Capital expenditures in the range of $80 million to $90 million release Jan 23, 2025
For 2025, giving effect to the acquisition of Nova Medical Centers, Concentra expects to deliver the following results: … Capital expenditures in the range of $80 million to $90 million release Mar 3, 2025
For 2025, Concentra now expects to deliver the following results: … Capital expenditures in the range of $80 million to $90 million (no change from initial guidance) release May 7, 2025
Revenue
Fiscal 2025 (ended Dec 31, 2025)
Given $2.10B to $2.15B release May 7, 2025
$2.16B
10-K filed 2026-02-26
Above the range
The company's words
For 2025, Concentra now expects to deliver the following results: … Revenue in the range of $2.1 billion to $2.15 billion release May 7, 2025
EBITDA (company-defined)
Fiscal 2024 (ended Dec 31, 2024)
Given $370.00M to $375.00M release Oct 31, 2024
– No standard number
The company's words
Concentra is issuing its 2024 business outlook. … Concentra expects revenue to be approximately $1.9 billion, Adjusted EBITDA to be in the range of $370.0 million to $375.0 million, capital expenditures to be in the range of $65.0 million to $70.0 million and our net leverage ratio to be in the range of 3.5 to 3.6x. release Oct 31, 2024
Capital expenditures
Fiscal 2024 (ended Dec 31, 2024)
Given $65.00M to $70.00M release Oct 31, 2024
$64.33M
10-K filed 2025-03-03
Below the range
The company's words
Concentra is issuing its 2024 business outlook. … Concentra expects revenue to be approximately $1.9 billion, Adjusted EBITDA to be in the range of $370.0 million to $375.0 million, capital expenditures to be in the range of $65.0 million to $70.0 million and our net leverage ratio to be in the range of 3.5 to 3.6x. release Oct 31, 2024

Targets are read from the sentences of the EX-99 exhibits of 8-K item 2.02 filings (13 releases since 2024-08-01), without AI; in outlook tables only the first column is read. The result compares the reported number with the last range given before the period was reported. Results come from SEC's XBRL company facts, as first reported. A company's target can use its own definition (META's capital expenditures include finance lease payments, for example), so read the quote.

Sources

The outlook sentences of each earnings release (8-K item 2.02, exhibit 99), read without AI; results from SEC's XBRL company facts, as first reported.

Also

Earnings releases: each release in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/CON/export.csv") into a cell.

Next:Archive
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.